EUVIMEDEUVIMED entdecken
Open Access

Maternal Prenatal Cannabis Use and Child Autism Spectrum Disorder

Lyndsay A Avalos, Mahlet Shenkute, Stacey E Alexeeff, Nina Oberman, Lisa A Croen, Meghan Davignon, Sara R Adams, Deborah Ansley, Carley Castellanos, Kelly C Young-Wolff

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.40301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Lyndsay A Avalos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Research, Kaiser Permanente Northern California, Pleasanton. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Prenatal Exposure Delayed Effects. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IMPORTANCE Despite an increase in maternal prenatal cannabis use and associations with adverse neonatal outcomes, research on child neurodevelopmental outcomes is limited. OBJECTIVE To evaluate the association between maternal cannabis use in early pregnancy and child autism spectrum disorder (ASD). DESIGN, SETTING, and PARTICIPANTS This population-based retrospective birth cohort study included children born between 2011 and 2019 to pregnant Kaiser Permanente Northern California members screened for prenatal cannabis use during pregnancy. Statistical analysis was conducted February 2023 to March 2024. EXPOSURES Maternal prenatal cannabis use was assessed at entrance to prenatal care (approximately 8- to 10-weeks’ gestation) via self-report and/or positive urine toxicology test. Use frequency was assessed. Main Outcomes and Measures Child ASD was defined by International Statistical Classification of Diseases and Related Health Problems, Tenth Revision ( ICD-10 ) diagnosis codes ascertained from the electronic health record. Associations between maternal prenatal cannabis use and child ASD were modeled using Cox proportional hazards regression adjusted for maternal sociodemographic, other substance use and disorders, prenatal care initiation, comorbidities, and clustering among maternal siblings. RESULTS The study cohort included 178 948 singleton pregnancies among 146 296 unique pregnant individuals, including 48 880 (27.3%) Asian or Pacific Islander, 42 799 (23.9%) Hispanic, 9742 (5.4%) non-Hispanic Black, and 70 733 (39.5%) non-Hispanic White pregnancies. The median (IQR) maternal age at pregnancy onset was 31 (6) years; 8486 (4.7%) screened positive for cannabis use, 7054 (3.9%) via urine toxicology testing and 3662 (2.0%) by self-report. In the total study population, the frequency of self-reported use was monthly or less for 2003 pregnancies (1.1%), weekly for 918 pregnancies (0.5%), daily for 741 pregnancies (0.4%), and unknown for 4824 pregnancies (2.7%). ASD was diagnosed in 3.6% of children. After adjustment for maternal characteristics, maternal prenatal cannabis use was not associated with child ASD (hazard ratio [HR], 1.05; 95% CI, 0.84-1.32). When self-reported frequency of use was assessed, no statistically significant associations were observed after confounder adjustment. No sex-specific associations were documented (males: HR, 1.01; 95% CI, 0.77-1.32; and females: HR, 1.19; 95% CI, 0.77-1.85). CONCLUSIONS and Relevance In this cohort study, maternal cannabis use assessed in early pregnancy was not associated with child ASD. Additional studies are needed to evaluate different patterns of use throughout pregnancy. Given the known adverse neonatal health effects of maternal prenatal cannabis use, clinicians should follow national guidelines and advise against use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autism Spectrum DisorderPrenatal Exposure Delayed EffectsHumansFemalePregnancyRetrospective StudiesAdultCaliforniaMaleChildPregnancy ComplicationsChild, PreschoolMarijuana UseCohort Studies

Autor:innen und Institutionen

  • Division of Research, Kaiser Permanente Northern California, Pleasanton.
  • Bernard J. Tyson Kaiser Permanente School of Medicine, Pasadena, California.
  • Kaiser Permanente Roseville Medical Center, Pediatric Subspecialties; Regional Medical Director of Pediatric Developmental Disabilities, Roseville, California.
  • Regional Offices, Kaiser Permanente Northern California, Oakland.
  • Department of Psychiatry and Behavioral Sciences, University of California, San Francisco.

Förderung

  • NIDA NIH HHS

Zitieren

APA

Avalos, L. A., Shenkute, M., Alexeeff, S. E., Oberman, N., Croen, L. A., Davignon, M., Adams, S. R., Ansley, D., Castellanos, C., & Young-Wolff, K. C. (2024). Maternal Prenatal Cannabis Use and Child Autism Spectrum Disorder. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.40301

Vancouver

Avalos LA, Shenkute M, Alexeeff SE, Oberman N, Croen LA, Davignon M, et al. Maternal Prenatal Cannabis Use and Child Autism Spectrum Disorder. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.40301

BibTeX
@article{Avalos2024,
  author = {Avalos, Lyndsay A and Shenkute, Mahlet and Alexeeff, Stacey E and Oberman, Nina and Croen, Lisa A and Davignon, Meghan and Adams, Sara R and Ansley, Deborah and Castellanos, Carley and Young-Wolff, Kelly C},
  title = {Maternal Prenatal Cannabis Use and Child Autism Spectrum Disorder},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.40301}
}
Kostenlos starten →